Abstract
Magnetic seizure therapy (MST) is a potential alternative to electroconvulsive therapy (ECT), but there is currently a lack of reports about MST in Chinese patients with schizophrenia. Our objective was to investigate the feasibility and acceptability of add-on MST in the treatment of patients with schizophrenia. Eight patients with schizophrenia were enrolled in a case series study to receive 10 sessions of add-on MST over 4 weeks. The MST was administrated using 25 Hz at 100% output with a titration duration ranging from 4 to 20 s by 4 s. The Positive and Negative Syndrome Scale (PANSS) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) were employed to measure the symptom improvements and the cognitive effects, respectively. Six patients completed at least one-half of the planned sessions. Five showed a reduction in PANSS total score, and three achieved clinical response (≥30% reduction). Three of the participants receiving the RBANS, showed either improvements or no changes in the memory function. Regarding the subjective complaints about MST, two reported dizziness, and only one reported memory loss. Approximately one-fourth of the treatment sessions produced only brief seizures (<15 s). Overall, employing MST to treat Chinese patients with schizophrenia appeared feasible and acceptable. However, further evidence is needed to determine the therapeutic efficacy and effects of MST on the cognitive functions of patients with schizophrenia.
Introduction
Schizophrenia affects millions globally, with approximately 30% of patients failing to respond adequately to standard antipsychotic medications. While Electroconvulsive Therapy (ECT) is a powerful tool for treatment-resistant cases, it is associated with a significant "cognitive tax," including persistent memory loss and post-treatment disorientation. These side effects occur because the skull acts as a high-resistance barrier, forcing electrical stimuli to spread widely across the brain.
Magnetic Seizure Therapy (MST) offers a more focal approach. Because magnetic fields pass through the scalp and skull without resistance, they can be targeted to specific cortical regions. The goal is to induce the therapeutic seizure necessary for psychiatric improvement while sparing the hippocampus and other regions responsible for memory. While MST has shown promise in treating depression, its efficacy and feasibility in Chinese patients with schizophrenia remained unexplored until this study.
Methods
The researchers conducted an open-label, self-controlled case series at the Shanghai Mental Health Center involving eight inpatients (ages 18–55). Patients received 10 sessions of MST over four weeks under general anesthesia.
The hardware utilized was a MagPro X100 stimulator with a twin coil placed on the vertex to induce a deep, focal electric field (see Figure 1). Stimuli were delivered at 25 Hz with 100% output. The researchers used a titration method, starting at 4 seconds and increasing duration by 4 seconds in subsequent sessions (up to 20s) if seizure quality was poor.
Clinical symptoms were measured using the Positive and Negative Syndrome Scale (PANSS), while cognitive function was tracked via the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
Results
The study demonstrated a significant "cognitive sparing" success. Unlike ECT, MST participants showed either no change or actual improvement in memory scores on the RBANS. Only one patient reported subjective memory loss, and two reported mild dizziness.
Regarding clinical efficacy, three out of the eight patients (37.5%) achieved a clinical response (≥30% reduction in PANSS scores). For the six patients who completed the majority of the sessions, the mean PANSS total score dropped from 97.25 to 71.5. Individual trajectories for both total and positive symptom scores are visualized in Figure 2.
However, seizure quality was a major challenge. While the mean EEG seizure duration was 17.29 seconds, approximately 23.2% of sessions resulted in "brief seizures" (<15s), which are generally considered less effective. One patient failed to have any seizure at all, even at maximum stimulation.
Discussion and Conclusion
While 25 Hz MST is feasible and well-tolerated by Chinese patients with schizophrenia, it does not appear to be optimal. The 37.5% response rate is notably lower than the ~70% typically seen with ECT. The authors suggest that 25 Hz may be too low for this population, as patients with schizophrenia often have higher seizure thresholds that may be further elevated by previous ECT treatments.
Future trials should explore higher frequencies (up to 100 Hz) and larger sample sizes to determine if increasing the stimulation "dose" can match ECT's efficacy while maintaining MST's superior safety profile. Further research incorporating neuroimaging (fMRI) is also planned to better understand the underlying physiological changes.
Summary updated